Apollo Health Ventures

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.

Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.

HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.

Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is a pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend a healthy lifespan.

Aeovian Pharmaceuticals is a San Francisco-based biopharmaceutical company focused on the research and development of innovative therapeutics for rare and age-related diseases. Founded in 2012, the company aims to discover and commercialize compounds that modulate key molecular pathways, specifically targeting the mTORC1 and mTORC2 pathways. By addressing the underlying causes of disease initiation and progression—such as oxidative, cellular, and environmental stress—Aeovian Pharmaceuticals seeks to provide effective treatments that improve patient outcomes.

Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is a pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend a healthy lifespan.

Cleara is developing therapeutics to eliminate senescent cells.

Aeovian Pharmaceuticals is a San Francisco-based biopharmaceutical company focused on the research and development of innovative therapeutics for rare and age-related diseases. Founded in 2012, the company aims to discover and commercialize compounds that modulate key molecular pathways, specifically targeting the mTORC1 and mTORC2 pathways. By addressing the underlying causes of disease initiation and progression—such as oxidative, cellular, and environmental stress—Aeovian Pharmaceuticals seeks to provide effective treatments that improve patient outcomes.